Prostate Cancer : Episode 5

Video

Episode 5 - Pharmacoeconomic Considerations

During this discussion, Jeffrey D. Dunn, PharmD, MBA, explains how the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer (CRPC) has increased the amount of pharmacoeconomic spending in the United States.

Because there are several options available, and because clinicians have different treatment preferences, Michael Kolodziej, MD, discusses why it is necessary to determine a proper sequencing plan before administering treatment.

Raoul S. Concepcion, MD, agrees that drug sequencing is a major challenge. However, he believes that because so many treatment options are available, clinicians need to individualize therapy when treating patients with CRPC.

Dr Dunn, Dr Concepcion, and David Quinn, MD, review the costs of new agents and discuss why it is important for insurers to provide coverage toward research that tests drug sequencing.


Related Videos
dr jennifer vidrine
dr brian koffman
mily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center
Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center
dr thomas hall
Neal Shore, MD, FACS, an expert on bladder cancer
Neal Shore, MD, FACS, an expert on bladder cancer
RAvin Ratan, MD, MEd, MD Anderson
Amy Shapiro, MD
Related Content
CH LogoCenter for Biosimilars Logo